Endlich wieder frei atmen

Complementary Medicine, 2003, 9, S. 243–249
    Hennekens, C. H.; Buring, J. E.; Manson, J. E.; Stampfer, M.; Rosner, B.; Cook, N. R. et al.: „Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease“, New English Journal of Medicine, 1996, 334, S.1145–1149
    Iqbal, F.; Michaelson, J.; Thaler, L. et al: „Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function“, Chest, 1999, 116, 1616–1624
    Juergens, U. R.; Dethlefsen, U.; Steinkamp, G.; Gillissen, A.; Repges, R.; Vetter, H.: „Anti-inflammatory activity of 1,8-Cineol (eucalyptol) in bronchialasthma: a double-blind placebo-controlled trial“, Respiratory Medical Medicine, 2003, 97, S. 250–256
    Katsura, H.; Kida, K.: „A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma“, Chest, 2002, 122, S. 1949–1955
    Kim, Y. S.; Eo, S. K.; Oh, K. W.; Lee, C.; Han, S. S.: „Antiherpetic activities of acidic protein-bound polysacchride isolated from Ganoderma lucidum alone and in combinations with interferons“, Journal of Ethnopharmacology, 2000, 72, S. 451–458
    Knobloch, J.; Sibbing, B.; Jungck, D.; Lin, Y.; Urban, K.; Stoelben, E.; Strauch, J.; Koch, A.: „Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in COPD“, American Society for Pharmacology and Experimental Therapeutics, 2010, doi: 10.1124/jpet.110.166843
    Lee, I. M.; Cook, N. R.; Manson, J. E.: „Beta-carotene supplementation and incidence of cancer and cardiovascular disease: Women’s Health Study“, Journal of National Cancer Institute, 1999, 91, S. 2102–2106
    Miravitlles, M.; Mayordomo, C.; Artés, M.; Sanchez-Agudo, L.; Nicolau, F.; Segú, J.-L.: „Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice“, Respiratory Medicine, 1999, 93, S. 173–179
    National Institute for Clinical Excellence: „Chronic obstructive pulmonary disease: management of adults with chronic obstructive pulmonary disease in primary and secondary care“, www.nice.org.uk
    Ng, T. P. et al: „Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life“, Archive of International Medicine, 2007,167(1), S. 60–67
    Omenn, G. S.; Goodman, G.; Thomquist, M. et al: „The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers“, Cancer Research, 1994, 54, S. 2038s–2043s
    Pauwels, R. A.; Buist, A. S.; Calverley, P. M. A.; Jenkins, C. R.; Hurd, S. S.: „Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease“,
American Journal of Respiratory Critical Care Medicine
, 2001, 163, S. 1256–1276
    Petty, T. L.; Nett, L. M.: „Save Your Breath, America!“, www.nlhep.org/lung.htm
    The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: „The effects of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers“, New England Journal of Medicine, 1994, 330, S. 1029–1035
    Wang Y. Y.; Khoo K. H.; Chen S. T. et al.: „Studies on the immunomodulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities“, Bioorganic Medical Chemistry, 2002, 10, S. 1057–1062
    Wicks S. M.; Tong R.; Wang C. Z. et al: „Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial“, American Journal of Chinise Medicine, 2007, 35, S. 407–414
    Worth H.; Buhl, R.; Cegla U. et al.: „Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)“, Pneumologie, 2002, 56, S. 704–738

Ein Schlusswort
    Trotz der immens hohen Anzahl COPD-Erkrankter gibt es nur wenig Fortschritte in der „schulmedizinischen“ Therapie dieser Lungenerkrankungen. War die Forschung bis Ende der 1990er-Jahre mehr als schleppend, ist man jetzt immer stärker bemüht, neue Wirkstoffe zu entwickeln. Jedoch zeigen neue Innovationen zum Teil nicht tolerierbare Nebenwirkungen,